Several studies have investigated polymorphisms in @entity4187 and @entity0 risk with inconsistent results. We have carried out a population based case-control study of the @entity69400 and @entity34321 polymorphisms in @entity4187 to clarify their importance in determining @entity0 susceptibility. A total of 1873 cases and 712 controls were genotyped for @entity69400 and 1948 cases and 1355 controls were genotyped for @entity34321 . We have also investigated a putative interaction between smoking and @entity4187 genotype and @entity0 risk using a case only study design. The genotype distribution of @entity69401 in controls was close to that expected under Hardy-Weinberg equilibrium (HWE). We detected no significant differences in genotype frequencies between @entity0 cases and controls (P = 0.68). Compared with the Thr/Thr homozygotes there was no significant risk for either the Thr/ @entity2574 heterozygote [OR = 1.1 (95% CI 0.8-1.4)] or the @entity2574 / @entity2574 homozygote [OR = 0.4 (0.02-6.1)]. The genotype distribution of @entity34321 in controls was also close to that expected under HWE with no significant differences between @entity0 cases and the controls (P = 0.44). No significant risk was found for either the Ile/ @entity2596 heterozygote [OR = 0.8 (0.6-1.1)] or the @entity2596 / @entity2596 homozygote [OR = 2.7 (0.3-24)] compared with the Ile/Ile homozygotes. Furthermore, subgroup analyses revealed no effect of age or menopausal status on genotypic risks, and we found no evidence for an interaction between genotype and smoking habit or @entity167 consumption and susceptibility to @entity0 . We combined our data for the @entity34321 polymorphism with those from four other published studies, but even with >5000 subjects, none of the genotype-associated risks achieved statistical significance, and there was no consistent pattern to the risks associated with increasing @entity2596 allele dosage [Ile/ @entity2596 OR = 0.9 (0.7-1.1), @entity2596 / @entity2596 OR = 2.3 (0.4-12), and @entity2596 carrier OR = 1.0 (0.9-1.1)].

Polymorphisms in XXXX and smoking: no association with @entity0 risk.

@entity2574 :: ('CHEBI:22660', 'Chemical') :: ['Asp'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity4187 :: ('1543', 'Gene') :: ['CYP1A1'] @entity69400 :: ('p|SUB|T|461|N', 'ProteinMutation') :: ['Thr461Asn'] @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol'] @entity69401 :: ('p|SUB|T|461|D', 'ProteinMutation') :: ['Thr461Asp'] @entity2596 :: ('CHEBI:16414', 'Chemical') :: ['Val'] @entity34321 :: ('p|SUB|I|462|V', 'ProteinMutation') :: ['Ile462Val']
@entity4187 :: (1543,Gene) :: ['CYP1A1']
